Nektar Therapeutics (NASDAQ: NKTR). Extremely significant negative changes in investment behavior have recently occurred: negative upside/downside volume developed, and the stock fell on very heavy volume.
Recent significant negative changes in fundamentals have affected Nektar Therapeutics (NASDAQ: NKTR): significant quarterly sales deceleration occurred, and significant quarterly earnings deceleration occurred.
In light of these highly negative signals we are reviewing our current Overall Rating of F. We would continue to view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, NKTR is expected to continue to be a major Value Eraser.
Nektar Therapeutics has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Nektar Therapeutics has a poor Appreciation Score of 24 and a very low Power Rating of 11, resulting in the Lowest Value Trend Rating.
Recent Price Action
Nektar Therapeutics (NASDAQ: NKTR) stock suffered a very large decline of -6.0% on 10/2/19. The shares closed at $17.33. Moreover, this decline was accompanied by exceptionally high trading volume at 1015% of normal. The stock has declined -8.4% during the last week and has been extremely weak relative to the market over the last nine months.